©2022 Stanford Medicine
Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)
Trial ID: NCT00450385
The investigators hypothesize that survival of newly diagnosed DLBCL (diffuse large B-cell lymphoma) patients treated with R-CHOP can be predicted by RNA or protein gene expression or by presence of biomarkers associated with the anti-tumor effects of Rituximab.
Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP
- 1. Diagnosis of diffuse large B-cell lymphoma, CD20-positive, according to the World
Health Organization Classification, stages II-IV or limited stage I disease that is
bulky (more than 10 cm) or with International Prognostic Index (IPI) score > 1.
- 2. Patients must not have had prior chemotherapy, radiotherapy or immunotherapy. A
short course (< 2 weeks) of corticosteroids is allowed.
- 3. Adequate paraffin-embedded tumor specimen must be available for gene expression
analysis and immunohistochemistry prior to initiation of therapy. (If the specimen is
deemed inadequate, the subject can be retroactively screen failed, as this does not
change the treatment regimen).
- 4. Baseline measurements and evaluation must be obtained within 4 weeks before first
- 5. Age >18 years.
- 6. Eastern Cooperative Oncology Group (ECOG) performance status 0-3.
- 7. Adequate organ function:
- White Blood Cells count (WBC) >2500/µL
- Absolute Neutrophil Count (ANC) > 1000/µL (unless due to disease in marrow)
- platelet count >100,000/µL (unless due to disease in marrow)
- creatinine < 2.0 mg/dL,
- bilirubin < 1.5 mg/dL (may be 1.5-3.0 mg/dl if due to liver involvement by
- Serum Glutamic Oxaloacetic Transaminase (SGOT)/ Serum Glutamic Pyruvic
Transaminase (SGPT) <3 x upper limit of normal.
- 8. Female patients must not be pregnant or breast feeding.
- 9. Women of childbearing potential and men must be strongly advised to use an accepted
and effective method of contraception.
- 10. Patients must have left ventricular ejection fraction of >45%.
- 11. Provision of written informed consent.
- 1. Patients with a second malignancy other than basal cell carcinoma of the skin or in
situ carcinoma of the cervix unless the tumor was treated with curative intent at
least two years previously; and; the patient continue to be free of evidence of
- 2. Patients with HIV infection as these patients are managed on dedicated protocols.
- 3. Patients with active central nervous system (CNS) lymphoma.
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office